Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT07250386
First seen Jan 05, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This early-phase study tests a new treatment called CAR-T cells, which are immune cells engineered to target a protein called CEA found on certain cancer cells. The study includes up to 48 adults with advanced non-small cell lung cancer or breast cancer that has not responded to standard therapies. The main goals are to check the safety of the treatment and find the best dose, while also seeing if it can shrink or control the tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310017, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.